According to the Zhitong Finance App, China Biotech Services (08037.HK) announced that the Group is expected to obtain a net profit of not less than HK$15 million within the six months ending June 30, 2026. In contrast, the net loss for the six months ended June 30, 2025 was approximately HK$37 million. The anticipated shift from net loss to net profit is mainly due to possible non-cash and unrealized fair value gains of HK$77 million to HK$87 million on convertible bonds, which were offset by (i) an increase in financing costs of approximately HK$9 million due to the company's issuance of convertible bonds with a principal amount of US$35 million in February 2026; (ii) no non-recurring compensation income of approximately HK$14 million (which was recognized as other income in the same period in 2025).
Zhitongcaijing · 1d ago
Share
Listen to the news
According to the Zhitong Finance App, China Biotech Services (08037.HK) announced that the Group is expected to obtain a net profit of not less than HK$15 million within the six months ending June 30, 2026. In contrast, the net loss for the six months ended June 30, 2025 was approximately HK$37 million. The anticipated shift from net loss to net profit is mainly due to possible non-cash and unrealized fair value gains of HK$77 million to HK$87 million on convertible bonds, which were offset by (i) an increase in financing costs of approximately HK$9 million due to the company's issuance of convertible bonds with a principal amount of US$35 million in February 2026; (ii) no non-recurring compensation income of approximately HK$14 million (which was recognized as other income in the same period in 2025).
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending